{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:42:46Z","timestamp":1790181766688,"version":"4.1.0"},"reference-count":58,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2019.7446","type":"journal-article","created":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T16:31:10Z","timestamp":1553704270000},"source":"Crossref","is-referenced-by-count":8,"title":["Population pharmacokinetics of tacrolimus in pediatric refractory nephrotic syndrome and a summary of other pediatric disease models"],"prefix":"10.3892","author":[{"given":"Dongdong","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Children's Hospital of Fudan University, Shanghai 201102, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinmiao","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Children's Hospital of Fudan University, Shanghai 201102, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Children's Hospital of Fudan University, Shanghai 201102, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiping","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Children's Hospital of Fudan University, Shanghai 201102, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2019,3,27]]},"reference":[{"key":"key20200713120805_b1-etm-0-0-7446","first-page":"333","article-title":"Recent insights into the pathogenesis of nephrotic syndrome","volume":"104","author":"Certikova-Chabova","year":"2013","journal-title":"Minerva Med"},{"key":"key20200713120805_b2-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(03)14184-0","article-title":"Nephrotic syndrome in childhood","volume":"362","author":"2. Eddy","year":"2003","journal-title":"Lancet"},{"key":"key20200713120805_b3-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1007\/s004670100021","article-title":"Time trends and ethnic patterns of childhood nephrotic syndrome in Yorkshire, UK","volume":"16","author":"McKinney","year":"2001","journal-title":"Pediatr Nephrol"},{"key":"key20200713120805_b4-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1136\/adc.57.7.544","article-title":"Long-term outcome of primary nephrotic syndrome","volume":"57","author":"Koskimies","year":"1982","journal-title":"Arch Dis Child"},{"key":"key20200713120805_b5-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00467-012-2310-x","article-title":"Improving Global Outcomes: Treatment of steroid-sensitive nephrotic syndrome: New guidelines from KDIGO","volume":"28","author":"Lombel","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"key20200713120805_b6-etm-0-0-7446","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1681\/ASN.V85769","article-title":"Prognostic significance of the early course of minimal change nephrotic syndrome: Report of the International Study of Kidney Disease in Children","volume":"8","author":"Tarshish","year":"1997","journal-title":"J Am Soc Nephrol"},{"key":"key20200713120805_b7-etm-0-0-7446","first-page":"CD001533","article-title":"Corticosteroid therapy for nephrotic syndrome in children","author":"Hodson","year":"2007","journal-title":"Cochrane Database Syst Rev (4)"},{"key":"key20200713120805_b8-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1053\/j.ajkd.2008.11.033","article-title":"Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: A randomized controlled trial","volume":"53","author":"Choudhry","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"key20200713120805_b9-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1038\/ki.2012.238","article-title":"Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome","volume":"82","author":"Gulati","year":"2012","journal-title":"Kidney Int"},{"key":"key20200713120805_b10-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1093\/ndt\/gfm688","article-title":"Tacrolimus: A new therapy for steroid-resistant nephrotic syndrome in children","volume":"23","author":"Gulati","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"key20200713120805_b11-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00467-003-1370-3","article-title":"Tacrolimus therapy in pediatric patients with treatment-resistant nephrotic syndrome","volume":"19","author":"Loeffler","year":"2004","journal-title":"Pediatr Nephrol"},{"key":"key20200713120805_b12-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s00467-010-1471-8","article-title":"Long-term outcome of children with steroid-resistant nephrotic syndrome treated with tacrolimus","volume":"25","author":"Roberti","year":"2010","journal-title":"Pediatr Nephrol"},{"key":"key20200713120805_b13-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.kint.2017.01.019","article-title":"Mycophenolate mofetil is inferior to tacrolimus in sustaining remission in children with idiopathic steroid-resistant nephrotic syndrome","volume":"92","author":"Sinha","year":"2017","journal-title":"Kidney Int"},{"key":"key20200713120805_b14-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1007\/s00467-012-2228-3","article-title":"Treatment of tacrolimus or cyclosporine A in children with idiopathic nephrotic syndrome","volume":"27","author":"Wang","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"key20200713120805_b15-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s12519-015-0062-y","article-title":"Tacrolimus for children with refractory nephrotic syndrome: A one-year prospective, multicenter, and open-label study of Tacrobell\u00ae, a generic formula","volume":"12","author":"Yang","year":"2016","journal-title":"World J Pediatr"},{"key":"key20200713120805_b16-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"404","DOI":"10.2165\/00003088-199529060-00003","article-title":"Clinical pharmacokinetics of tacrolimus","volume":"29","author":"Venkataramanan","year":"1995","journal-title":"Clin Pharmacokinet"},{"key":"key20200713120805_b17-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1097\/00007691-199512000-00011","article-title":"Consensus document: Therapeutic monitoring of tacrolimus (FK-506)","volume":"17","author":"Jusko","year":"1995","journal-title":"Ther Drug Monit"},{"key":"key20200713120805_b18-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/jcpt.12396","article-title":"Population pharmacokinetics of tacrolimus in Thai kidney transplant patients: Comparison with similar data from other populations","volume":"41","author":"Vadcharavivad","year":"2016","journal-title":"J Clin Pharm Ther"},{"key":"key20200713120805_b19-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/FTD.0000000000000134","article-title":"Development of a population PK model of tacrolimus for adaptive dosage control in stable kidney transplant patients","volume":"37","author":"Andreu","year":"2015","journal-title":"Ther Drug Monit"},{"key":"key20200713120805_b20-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"683","DOI":"10.2165\/11535950-000000000-00000","article-title":"Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation","volume":"49","author":"Benkali","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"key20200713120805_b21-etm-0-0-7446","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/FTD.0b013e31829f1ab8","article-title":"Population pharmacokinetics of tacrolimus in adult kidney transplant patients: Impact of CYP3A5 genotype on starting dose","volume":"36","author":"Bergmann","year":"2014","journal-title":"Ther Drug Monit"},{"key":"key20200713120805_b22-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/bcpt.12176","article-title":"Population pharmacokinetic-pharmacogenetic model of tacrolimus in the early period after kidney transplantation","volume":"114","author":"Han","year":"2014","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"key20200713120805_b23-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/clpt.2009.210","article-title":"Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients","volume":"86","author":"Zhao","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"key20200713120805_b24-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/FPC.0b013e32835fcbb6","article-title":"Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: A population pharmacokinetic analysis","volume":"23","author":"Zuo","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"key20200713120805_b25-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/aps.2014.110","article-title":"A population pharmacokinetic study of tacrolimus in healthy Chinese volunteers and liver transplant patients","volume":"36","author":"Lu","year":"2015","journal-title":"Acta Pharmacol Sin"},{"key":"key20200713120805_b26-etm-0-0-7446","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/FTD.0b013e31829dcbcd","article-title":"Population pharmacokinetic analysis of tacrolimus early after pediatric liver transplantation","volume":"36","author":"Musuamba","year":"2014","journal-title":"Ther Drug Monit"},{"key":"key20200713120805_b27-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1097\/FTD.0b013e31823415cc","article-title":"Population pharmacokinetics of tacrolimus in pediatric liver transplantation: Early posttransplantation clearance","volume":"33","author":"Wallin","year":"2011","journal-title":"Ther Drug Monit"},{"key":"key20200713120805_b28-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"75","DOI":"10.5414\/CP202189","article-title":"Population pharmacokinetic analysis of tacrolimus early after Chinese pediatric liver transplantation","volume":"53","author":"Yang","year":"2015","journal-title":"Int J Clin Pharmacol Ther"},{"key":"key20200713120805_b29-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/FTD.0b013e31824a67eb","article-title":"The impact of sulfonylureas on tacrolimus apparent clearance revealed by a population pharmacokinetics analysis in Chinese adult liver-transplant patients","volume":"34","author":"Zhang","year":"2012","journal-title":"Ther Drug Monit"},{"key":"key20200713120805_b30-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"840","DOI":"10.3109\/00498254.2015.1021733","article-title":"Effects of CYP3A5 genotypes, ABCB1 C3435T and G2677T\/A polymorphism on pharmacokinetics of Tacrolimus in Chinese adult liver transplant patients","volume":"45","author":"Zhu","year":"2015","journal-title":"Xenobiotica"},{"key":"key20200713120805_b31-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1097\/FTD.0b013e3181aab02b","article-title":"Population pharmacokinetics of tacrolimus in pediatric hematopoietic stem cell transplant recipients: New initial dosage suggestions and a model-based dosage adjustment tool","volume":"31","author":"Wallin","year":"2009","journal-title":"Ther Drug Monit"},{"key":"key20200713120805_b32-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2165\/11594760-000000000-00000","article-title":"Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation","volume":"51","author":"Monchaud","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"key20200713120805_b33-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.clpt.2006.06.008","article-title":"Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients","volume":"80","author":"Fukudo","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"key20200713120805_b34-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2165\/00003088-200140010-00005","article-title":"Covariate effects on the apparent clearance of tacrolimus in paediatric liver transplant patients undergoing conversion therapy","volume":"40","author":"Garc\u00eda S\u00e1nchez","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"key20200713120805_b35-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1007\/s00228-013-1501-0","article-title":"Population pharmacokinetic analysis of tacrolimus in the first year after pediatric liver transplantation","volume":"69","author":"Guy-Viterbo","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"key20200713120805_b36-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/bcp.12174","article-title":"Population pharmacokinetic and pharmacogenetic analysis of tacrolimus in paediatric liver transplant patients","volume":"77","author":"Jalil","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"key20200713120805_b37-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1111\/bcp.12276","article-title":"Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in paediatric liver transplant recipients","volume":"77","author":"Kassir","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"key20200713120805_b38-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1046\/j.1365-2125.2000.00288.x","article-title":"Population pharmacokinetics of tacrolimus in Asian paediatric liver transplant patients","volume":"50","author":"Sam","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"key20200713120805_b39-etm-0-0-7446","first-page":"1108","article-title":"Pharmacokinetics and pharmacodynamics of FK 506 in pediatric patients receiving living-related donor liver transplantations","volume":"27","author":"Yasuhara","year":"1995","journal-title":"Transplant Proc"},{"key":"key20200713120805_b40-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/0009-9236(95)90153-1","article-title":"Pharmacokinetics of tacrolimus in liver transplant patients","volume":"57","author":"Jusko","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"key20200713120805_b41-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","article-title":"PsN-Toolkit - a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM","volume":"79","author":"Lindbom","year":"2005","journal-title":"Comput Methods Programs Biomed"},{"key":"key20200713120805_b42-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/jcpt.12707","article-title":"Population pharmacokinetics of tacrolimus in paediatric systemic lupus erythematosus based on real-world study","volume":"43","author":"Wang","year":"2018","journal-title":"J Clin Pharm Ther"},{"key":"key20200713120805_b43-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","article-title":"Perl-speaks-NONMEM (PsN) - a Perl module for NONMEM related programming","volume":"75","author":"Lindbom","year":"2004","journal-title":"Comput Methods Programs Biomed"},{"key":"key20200713120805_b44-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2165\/00003088-200746030-00003","article-title":"Are population pharmacokinetic and\/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004","volume":"46","author":"Brendel","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"key20200713120805_b45-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.ejps.2005.01.002","article-title":"Mixed-effects modelling of the interspecies pharmacokinetic scaling of pegylated human erythropoietin","volume":"24","author":"Jolling","year":"2005","journal-title":"Eur J Pharm Sci"},{"key":"key20200713120805_b46-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"10","DOI":"10.2165\/00003088-199223010-00002","article-title":"Pharmacokinetic studies in paediatric patients. Clinical and ethical considerations","volume":"23","author":"Kauffman","year":"1992","journal-title":"Clin Pharmacokinet"},{"key":"key20200713120805_b47-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/sj.bmt.1702588","article-title":"Tacrolimus clearance is age-dependent within the pediatric population","volume":"26","author":"Przepiorka","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"key20200713120805_b48-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1093\/ndt\/gfl073","article-title":"Serum cystatin C as an endogenous marker of renal function in patients with mild to moderate impairment of kidney function","volume":"21","author":"Hojs","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"key20200713120805_b49-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1053\/ajkd.2002.34487","article-title":"Serum cystatin C is superior to serum creatinine as a marker of kidney function: A meta-analysis","volume":"40","author":"Dharnidharka","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"key20200713120805_b50-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1373\/clinchem.2004.041889","article-title":"Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: More than simply a marker of glomerular filtration rate","volume":"51","author":"Koenig","year":"2005","journal-title":"Clin Chem"},{"key":"key20200713120805_b51-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"R139","DOI":"10.1186\/cc3044","article-title":"Serum cystatin C concentration as a marker of acute renal dysfunction in critically ill patients","volume":"9","author":"Villa","year":"2005","journal-title":"Crit Care"},{"key":"key20200713120805_b52-etm-0-0-7446","first-page":"233","article-title":"Is serum Cystatin-C a suitable marker of renal function in children?","volume":"37","author":"Zaffanello","year":"2007","journal-title":"Ann Clin Lab Sci"},{"key":"key20200713120805_b53-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.cca.2008.02.004","article-title":"Comparative study of cystatin C and serum creatinine in the estimative of glomerular filtration rate in children","volume":"391","author":"Cordeiro","year":"2008","journal-title":"Clin Chim Acta"},{"key":"key20200713120805_b54-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.2217\/pgs.13.89","article-title":"Pharmacogenetics in solid organ transplantation: Genes involved in mechanism of action and pharmacokinetics of immunosuppressive drugs","volume":"14","author":"Kurzawski","year":"2013","journal-title":"Pharmacogenomics"},{"key":"key20200713120805_b55-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/00008571-200403000-00002","article-title":"The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients","volume":"14","author":"Haufroid","year":"2004","journal-title":"Pharmacogenetics"},{"key":"key20200713120805_b56-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0009-9236(03)00168-1","article-title":"Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus","volume":"74","author":"Hesselink","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"key20200713120805_b57-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1016\/j.clinthera.2010.11.010","article-title":"A prospective, open-label, observational clinical cohort study of the association between delayed renal allograft function, tacrolimus exposure, and CYP3A5 genotype in adult recipients","volume":"32","author":"Kuypers","year":"2010","journal-title":"Clin Ther"},{"key":"key20200713120805_b58-etm-0-0-7446","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/j.1742-7843.2008.00327.x","article-title":"Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients","volume":"103","author":"Quteineh","year":"2008","journal-title":"Basic Clin Pharmacol Toxicol"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T12:53:00Z","timestamp":1663159980000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2019.7446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,27]]},"references-count":58,"URL":"https:\/\/doi.org\/10.3892\/etm.2019.7446","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,27]]}}}